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Original Article
The predictive value of an adjusted
COPDassessment test scoreon the risk
of respiratory-related hospitalizations
in severe COPD patients
Joanne M Sloots1,2, Christopher A Barton3,
Julie Buckman4, Katherine L Bassett5,
Job van der Palen6,7, Peter A Frith5 and TanjaW Effing4,5
Abstract
We evaluated whether a chronic obstructive pulmonary disease (COPD) assessment test (CAT) with adjusted
weights for the CAT items could better predict future respiratory-related hospitalizations than the original
CAT. Two focus groups (respiratory nurses and physicians) generated two adjusted CAT algorithms. Two
multivariate logistic regression models for infrequent (1/year) versus frequent (>1/year) future respiratory-
related hospitalizations were defined: one with the adjusted CAT score that correlated best with future
hospitalizations and one with the original CAT score. Patient characteristics related to future
hospitalizations (p  0.2) were also entered. Eighty-two COPD patients were included. The CAT algorithm
derived from the nurse focus group was a borderline significant predictor of hospitalization risk (odds ratio
(OR): 1.07; 95% confidence interval (CI): 1.00–1.14; p ¼ 0.050) in a model that also included hospitalization
frequency in the previous year (OR: 3.98; 95% CI: 1.30–12.16; p ¼ 0.016) and anticholinergic risk score
(OR: 3.08; 95% CI: 0.87–10.89; p ¼ 0.081). Presence of ischemic heart disease and/or heart failure
appeared ‘protective’ (OR: 0.17; 95% CI: 0.05–0.62; p ¼ 0.007). The original CAT score was not
significantly associated with hospitalization risk. In conclusion, as a predictor of respiratory-related
hospitalizations, an adjusted CAT score was marginally significant (although the original CAT score was
not). ‘Previous respiratory-related hospitalizations’ was the strongest factor in this equation.
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Introduction
Chronic obstructive pulmonary disease (COPD) is a
common cause of disability, hospitalization and mor-
tality.1,2 COPD exacerbations are common and con-
tribute to disease progression,3 hospital admissions
and death among patients with COPD.4
The current Global Initiative for Chronic Obstruc-
tive Lung Disease (GOLD) Strategy recommends
categorizing patients’ risk of adverse outcomes by
evaluating not only the degree of airflow limitation
but also the past exacerbation frequency and the cur-
rent level of symptoms.5 This combined COPD
assessment is based on patient-centred outcomes that
can be assessed by validated measurements. How-
ever, performing spirometry is not always feasible,
especially in primary care settings.6,7
Health status is reported to be at least as important as
spirometry in predicting risk of exacerbations, hospita-
lizations and death.8 The COPD assessment test (CAT)
is one of the tools recommended by the GOLD
Strategy for evaluating overall health status and
documenting symptoms in patients with COPD.9 The
well-validated CAT contains eight items, which cover
common symptoms in patients with COPD, each
scored on a 5-point Likert scale.9 A higher summed
final score indicates worse health status. The CAT
score correlates well with the St. George’s Respiratory
Questionnaire10,11 and is responsive to pulmonary reha-
bilitation and recovery from COPD exacerbations.12,13
Clinicians in our hospital raised the question
whether the CAT score could also have predictive
value in clinic-based assessment of COPD patients.
Literature showed that slightly higher baseline CAT
scores were found in patients who were admitted to
the hospital 1 year after completing the CAT14 and in
patients having moderate to severe COPD exacerba-
tions during 6 months of follow-up.15 The CAT may
therefore also have predictive value in clinic-based
assessment in COPD patients.14,15
Currently, all CAT items are given the same weight
when calculating the overall CAT score. Literature
suggests, however, that some items might be more
strongly related to outcomes of disease severity than
others. Patients with COPD having chronic mucus
hypersecretion are, for example, at significantly higher
risk of COPD exacerbations,16,17 a common cause of
hospitalizations in patients with COPD.4,5 The items
cough and phlegm could therefore be expected to be of
more importance in predicting respiratory-related
events than other items.
In this study, we have investigated whether apply-
ing different weights to the individual CAT items
might strengthen associations between CAT scores
and respiratory-related hospitalizations in COPD
patients. We first developed and then applied several
algorithms to calculate adjusted CAT scores. These
algorithms were developed using qualitative analysis
of local experts’ opinions and then used to determine
a predictive model for future respiratory-related hos-
pitalizations. We hypothesized that an adjusted CAT
algorithm in which the individual CAT items have
different weights would be a stronger predictor of
future respiratory-related hospitalizations in patients
with COPD than the original CAT score.
Material and methods
Several algorithms were determined for calculating
adjusted CAT scores using focus group data. Subse-
quently, retrospective analyses were performed of
outpatient data from the departments of respiratory
medicine of the Repatriation General Hospital and the
Flinders Medical Centre, both within the Southern
Adelaide Local Health Network.
Study design
Providing CAT algorithms. Weightings for individual
CAT items were derived from qualitative analysis of
focus group discussions with health professionals.
One focus group was conducted with respiratory
nurses and another with advanced respiratory trainees
and respiratory physicians together. All participants
provided signed informed consent prior to participat-
ing in a single focus group.
At the start of each focus group, the demographic
and descriptive characteristics of participants and
information regarding their current CAT usage were
collected. Before and after the focus group discussion,
all participants were asked to write down the three
CAT items that they thought were most important and
another three they considered least important in rela-
tion to respiratory-related hospitalizations.
During the focus group discussions, all CAT items
were discussed and participants were asked if they
thought the items were more important or less important
in predicting the risk of respiratory-related hospitaliza-
tions and why. They were also asked to assign a weight
difference between the most and least important items.
Each focus group lasted approximately 1 hour. Investi-
gator CAB was the moderator of the focus groups;
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investigators TWE and JMS were present to observe the
discussion and to make notes. Each focus group discus-
sionwas audiotaped and later transcribed. After analysis,
a summaryof the focus groupdiscussion and the adjusted
item weightings were sent to the participants by e-mail.
Selection of patient data. Patient data were collected
retrospectively by screening case notes and searching
electronic patient databases between February and
June 2014. Three hospital databases were screened for
eligible patients: (a) patients in the Respiratory Inte-
grated Care Service (RICS), a nurse practitioner led
program directed towards intense case management
of COPD patients with high rates of hospitalizations
for COPD care; (b) patients receiving home oxygen
therapy for their respiratory disease; and (c) patients
visiting the outpatient clinic of a respiratory physician.
To be eligible for the current study, the patients had
to meet the following criteria: (a) having a clinical
diagnosis of COPD according to GOLD;5 (b) having
completed the CAT at least 6 months ago while being
in a stable phase of their COPD; (c) having no other
serious lung diseases; and (d) having no terminal dis-
eases (death likely within 12 months).
Approval for this study was given by the Southern
Adelaide Clinical Human Research Ethics Committee
(approval no. 553.13).
Sample size. Based on expert opinion, we assumed that
approximately 40% of the eligible patients (who had
advanced disease) would be frequently hospitalized in
the year after completing the CAT (defined as >1 hos-
pitalization per year) because of respiratory problems.
Assuming that a maximum of three characteristics
would be included in the final multivariate model, a
patient sample of approximately 80 was calculated to
be sufficient to determine the multivariate model.
Outcomes. The primary outcome for the multivariate
analyses was defined as the number of respiratory-
related hospitalizations in 12 months after completion
of the CAT.
Prior to the start of the study, literature was explored
to define which patient variables needed to be consid-
ered for multivariate analyses because of their associa-
tion with respiratory-related events (i.e. exacerbations,
hospitalizations and/or death; Figure 1).
Analyses
Focus groups. Immediately after each focus group, a
first CAT algorithm was made by the three
investigators present (CAB, TWE and JMS). Subse-
quently, two of the investigators (TWE and JMS)
independently provided a second algorithm for each
focus group using audio recordings and/or the written
focus group reports. The final algorithms were then
determined by all three investigators (CAB, TWE and
JMS) taking into account those previously defined
(n ¼ 3) for each focus group and the data regarding
the three most and least important items as marked by
the participants at the end of each focus group.
Weightings of the individual CAT items were
assigned a value higher than one where a majority
Lung function (measured by FEV1) (29,39,45)a
Dyspnea (measured by mMRC dyspnea scale) 21,26
Number of exacerbations in the previous year 28
Smoking status 29,46
Body mass index 29,47
Exercise capacity (measured by 6MWD) (48,49)b
Physical activity (23–25)c
Participation in a pulmonary rehabilitation programme 50
Anticholinergic risk scale (ARS)-score (18,30)d
The presence and total number of the following
comorbidities:e
– heart failure 17,51
– ischemic heart disease 17
– atrial fibrillation 17
– obstructive sleep apnoea syndrome 52
– depression 53,54
– anxiety 54
– diabetes mellitus 55–57
– gastro-oesophageal reflux 28,58,59
– cancer 60
Figure 1. COPD patient characteristics associated with
respiratory-related events (exacerbations/hospitalizations/
death) and collected for all included patients. COPD:
chronic obstructive pulmonary disease; FEV1: forced
expiratory volume; mMRC: modified Medical Research
Council dyspnoea scale; 6MWD: 6-minute walk distance.
aThe window for valid lung function tests was defined as
6 months before and 6 months after completion of the
CAT; if a lung function was not available in this window, it
was defined as a missing. bNot tested in univariate analysis
because of the high number of missing variables. cNot
collected because in most medical records physical activity
level was not clearly documented. dThe anticholinergic risk
scale (ARS)18 estimates the risk of anticholinergic adverse
effects of a drug (0: limited or no risk and 3: very strong
risk). The ARS of the individual prescribed drugs were
added up to provide the ARS score. The ARS score19 was
adjusted according to Rudolph et al.18 by adding the inhaled
agents tiotropium and ipratropium to the original ARS
score. eThe medical history of each patient was reviewed
to determine their co-morbidities.
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of focus group participants considered an item as
‘more important’ and lower than one if the majority
considered it ‘less important’.
Models. For patients with follow-up data of less than
12 months, hospitalization rate was adjusted by using
the following calculation: (12/number of months of
follow-up)  number of hospitalizations during
follow-up. Death was scored as a substitute for hospi-
talization for these patients. The number of hospitali-
zations was dichotomized:1 per year or >1 per year.
Data were presented as mean and standard
deviation (SD) for normally distributed continuous
variables, median and interquartile range (IQR) for
non-normal distributed continuous variables, and as
a number and percentages for categorical variables.
The original and adjusted CAT algorithms were
applied to raw CAT data to calculate original and
adjusted CAT scores. Univariate associations with the
respiratory-related hospitalization frequency were
then tested for these CAT scores and for the relevant
patient characteristics using Student t-tests, Wilcox-
on’s rank sum tests, w2 tests, Fisher’s exact tests and
Pearson/Spearman rank correlation tests, as appropri-
ate. The adjusted CAT algorithm that exhibited the
highest correlation with the frequency of respiratory-
related hospitalizations as well as patients’ character-
istics with a significance at or below p ¼ 0.2 were
then entered in a multivariate logistic regression anal-
ysis (bottom-up procedure). In case of multicollinear-
ity, the variable that was most relevant to the research
purpose was included. A second multivariate logistic
regression analysis was performed in which the orig-
inal CAT score was entered together with the patients’
characteristics that were entered in the first multivari-
ate model. The statistical analysis was performed with
IBM SPSS statistics version 20.
Results
Patient characteristics
There were 82 patients included in the study, 54%
(n ¼ 44) from the ‘home oxygen database’, 35%
(n ¼ 29) from the ‘Respiratory Integrated Care
Service database’, and 11% (n ¼ 9) from the respira-
tory physician clinic list. The total original CAT score
(oxygen database: 17.1 (SD: 5.8); RICS database:
20.7 (SD: 8.6); respiratory physician clinic list: 22.4
(SD: 7.3)) and the number of people with frequent
(>1) previous hospitalizations (oxygen database:
16%; RICS database: 86%; respiratory physician
clinic list: 11%) were significantly different between
the three databases (p < 0.05). Follow-up time for 13
patients was less than 12 months, while the median
follow-up time was 12 months (IQR: 12–12). Eight
deaths occurred in the period between completion of
the CAT and data collection. The baseline character-
istics of the patients are shown in Table 1.
Development of CAT algorithms
Five female nurses with a mean age of 41 years (SD:
11.1) and a mean working experience in the respira-
tory field of 9 years (SD: 5.6) participated in focus
group 1. Three of them used the CAT regularly (at
least once per week), one of them used it sometimes,
and one participant had used it regularly in the past.
Quotes from this focus group discussion and partici-
pants’ rankings of the importance of the different
CAT items in relation to respiratory-related hospita-
lizations are given in Table 2.
In focus group 2, four respiratory physicians
(three male) and two respiratory advanced trainees
(both female) participated. They had a mean age of
41 years (SD: 13.1) and a mean working experi-
ence in the respiratory field of 17 years (SD: 15.7).
None of the participants used the CAT regularly,
but all were aware of the content of the CAT.
Quotes from this focus group and participants’
rankings of the importance of the different CAT
items in relation to respiratory-related hospitaliza-
tions are given in Table 3.
The final weights for the two adjusted CAT algo-
rithms are listed in Table 4.
The predictive value of the CAT algorithms
in multivariate models
The results of the univariate analyses are given in
Tables 1 and 4. In the first multivariate regression
model for respiratory-related hospitalization risk
(Table 5), the adjusted CAT score based on weight-
ings developed from focus group 1 (respiratory
nurses) showed borderline significance controlling for
other variables with univariate significance p¼ 0.2 or
below. Patients with frequent hospitalizations (>1) in
the year prior to completing the CAT had an almost
four times higher risk of having frequent hospitaliza-
tions (>1) in the follow-up year. Patients with
ischemic heart disease and/or heart failure had a
significantly decreased risk of having frequent
respiratory-related hospitalizations in the following
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(1/year) (n ¼ 55)
Frequent
hospitalizations




Gender (male), n (%)1 38 (46) 27 (49) 11 (41) 0.476
Age, mean+ SD1 73.4 + 9.9 74.2+ 9.4 71.7+ 10.8 0.284
FEV1%, median (IQR)2 39 (31–45) 39 (31–46) 39 (25–45) 0.772
FEV1/FVC, median (IQR)2 34 (29–44) 35 (30–45) 33 (24–44) 0.369
GOLD stage3 0.042c,d
I, n (%) 1 (1) 1 (2) 1 (4)
II, n (%) 7 (9) 6 (11) 5 (19)
III, n (%) 28 (34) 23 (42) 10 (37)
IV, n (%) 25 (31) 15 (27) 11 (41)
GOLD category4
A, n (%) 0 0 0
B, n (%) 8 (10) 7 (13) 1 (4)
C, n (%) 6 (7) 4 (7) 2 (7)
D, n (%) 54 (66) 39 (71) 15 (56)
Presence of
Anxiety, n (%)5 19 (23) 11 (20) 8 (30) 0.354
Depression, n (%)5 18 (22) 11 (20) 7 (26) 0.571
Diabetes mellitus, n (%)5 13 (16) 9 (17) 4 (15) 1.000
Ischemic heart disease and/or heart failure, n (%)5,e 36 (44) 30 (55) 6 (22) 0.006c
Atrial fibrillation, n (%)5 18 (22) 13 (24) 5 (19) 0.571
Obstructive sleep apnoea syndrome, n (%)5 13 (16) 11 (20) 2 (7) 0.201
Gastro-oesophageal reflux disease, n (%)5 22 (27) 15 (28) 7 (26) 0.860
Cancer, n (%)5 17 (21) 10 (18) 7 (26) 0.440
At least one co-morbidity, n (%)5 69 (84) 45 (83) 24 (89) 0.742
Number of co-morbidities, median (IQR)5 2 (1–3) 2 (1–3) 2 (1–2) 0.498
ARS score6,f 0.042c,d
0, 1 and 2, n (%) 58 (71) 41 (75) 17 (63)
3, n (%) 18 (22) 8 (15) 10 (37)
Pulmonary rehabilitation year before/after
the CAT, n (%)5 13 (16) 10 (19) 3 (11) 0.528
Number of hospitalizations in prior year1 0.001c,d
1/year, n (%) 49 (60) 40 (73) 9 (33)
>1/year, n (%) 33 (40) 15 (27) 18 (67)
BMI, mean + SD7 27.8 + 7.3 28.2+ 7.0 26.7+ 8.0 0.417
Smoking status1
Never smokers, n (%) 2 (2) 2 (4) 0
Current smokers, n (%) 7 (8) 1 (2) 6 (22)
Ex-smokers, n (%) 73 (89) 52 (94) 21 (78)
Smoking history (pack years), median (IQR)8 40 (26–60) 38 (23–60) 44 (31–55) 0.433
mMRC dyspnoea scale9 0.114c,d
0, n (%) 1 (1) 0 1 (4)
1, n (%) 4 (5) 4 (7) 0
2, n (%) 12 (15) 10 (18) 2 (7)
3, n (%) 24 (29) 15 (27) 9 (33)
4, n (%) 17 (21) 10 (18) 7 (26)
Original CAT score, mean + SD1 18.9 + 7.3 18.0+ 6.4 20.9+ 8.7 0.094c
Number of months follow-up, median (IQR)1 12 (12–12) 12 (12–12) 12 (12–12) 0.670
Number of patientswith 12months of follow-up, n (%)1 69 (84) 47 (86) 22 (82) 0.750
Used database <0.001
(continued)
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year and the anticholinergic risk scale (ARS) score
(3) was positively related to respiratory-related hos-
pital admissions in the following year. The adjusted
CAT score contributed to the best fitted model (dif-
ference of 2 log-likelihood: 4.134 (p < 0.05)). This
model explained 36.4% of the variance. The modified
Medical Research Council dyspnoea scale was not
entered in the model because of the significant corre-
lation with the adjusted CAT score (p ¼ 0.04). The
GOLD stage was not included in the model because of
the high number of missing spirometry values.
In the second multivariate regression model
(Table 6), the original CAT score was not signifi-
cantly related to the frequency of respiratory-related
hospitalizations and did not contribute to the best
fitted model (difference of 2 log-likelihood: 3.50
(0.10 > p > 0.05)).
Discussion
Using a combination of qualitative (focus groups) and
quantitative analyses, this study found that using
adjusted weights for CAT items provided a better
predictor of the frequency of respiratory-related hos-
pitalizations in patients with COPD than using unad-
justed CAT scores. The adjusted CAT algorithm that
was based on information received from a focus group
with respiratory specialist nurses correlated best with
future respiratory-related hospitalizations.
In the adjusted CAT algorithm that correlated high-
est with future respiratory-related hospitalizations,
cough and phlegm received the highest weightings,
in line with published studies showing cough20 and
chronic mucus hypersecretion were strong predictors
for COPD exacerbations and death.8,16,17,20–22 Other
items allocated a weight higher than one in this algo-
rithm were ‘chest tightness’ and ‘doing activities at
home’. We were unable to find literature reports indi-
cating an association between chest tightness and hos-
pitalizations in patients with COPD. Several studies
have however confirmed that physical activity is asso-
ciated with exacerbations and hospital admissions.23–25
Results of our univariate analyses and literature both
indicate an association between dyspnoea and hospi-
talizations in COPD patients.26 Allocating a higher
weighting to the CAT item ‘breathlessness walking
up hills and stairs’ (which covers dyspnoea) may
therefore also improve the predictive value of the
adjusted CAT score further. In our study, however,
this item was not adjusted because it was not rated by
the focus group participants as more important than
other items.
The CAT was developed to assess the impact of
symptoms on the life of individual patients with
COPD.9,10 The CAT summary score was found to
correlate well with the St. George’s Respiratory
Questionnaire, a standard test of respiratory-related






(1/year) (n ¼ 55)
Frequent
hospitalizations




Oxygen database, n (%) 44 (54) 37 (67) 7 (26)
RICS database, n (%) 29 (35) 9 (16) 20 (74)
Patients’ pulmonary physician, n (%) 9 (11) 9 (16) 0
SD: standard deviation; IQR: interquartile range; n: number of patients; FEV1: forced expiratory volume in 1 second (litres); FEV1%:
percentage of predicted FEV1; FVC: forced vital capacity (litres); GOLD: Global Initiative for Chronic Obstructive Lung Disease; ARS:
anticholinergic risk scale; RICS: Respiratory Integrated Care Service; BMI: body mass index; mMRC: modified Medical Research Council
dyspnoea scale; CAT: COPD assessment test.
aIQR is reported as 25th–75th percentile.
bp-Value of univariate associations between patient characteristics and future hospitalization frequency (infrequent (1/year) vs.
frequent (>1/year)).
cVariable considered to be eligible in the multivariate logistic regression model based on p-value 0.200.
dp-Value of dichotomized variable: GOLD stage: I–III vs. IV (reason: low number of patients with GOLD stages I and II); mMRC score: 0,
1 and 2 vs. 3 and 4 (reason: low number of patients that scored 0 or 1); number of hospitalizations in prior year:1 hospitalizations per
year vs. >1 hospitalizations per year; ARS-score: 0–2 vs. 3.
eVariables ‘heart failure’ and ‘ischemic heart disease’ combined because of strong correlations between variables.
fThe ARS score19 was adjusted according to Rudolph et al.18 by adding the inhaled agents tiotropium and ipratropium to the original
ARS score.
1–9Patients with valid measures (n (% of total included patients)): 182(100), 246(56); 361(74); 468(83); 581(99); 676(93); 767(82); 877(94);
958(71).
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Responsiveness to pulmonary rehabilitation has been
demonstrated and a high CAT score appeared to be
associated with future hospitalizations.14,15,27 The
CAT therefore has a range of advantages, one of
which may be to predict risk of future hospitaliza-
tions. We did, however, not find a significant relation-
ship between the original CAT score and future
hospitalizations in this sample of patients with severe
COPD. Whereas the adjusted CAT score showed only
a borderline significant relationship with future
respiratory-related hospitalizations, the variable
nonetheless contributed to the best fitted model in the
prediction of respiratory-related hospitalizations in
our study. Because the odds ratio was low, though,
Table 2.Quotes of the focus group with respiratory nurses and their ‘importance’ rankings of the different CAT items in












‘Those other symptoms can fluctuate normally anyway. It is the phlegm change and the
cough change when you actually need to get action.’ (P1)
‘I think cough is probably one of the most important. Because if you don’t have a cough,
you don’t have phlegm.’ (P3)
‘I would say change in cough is more a red flag than change in phlegm or chest
tightness.’ (P3)
Chest tightness 2 1 ‘Cough, phlegm and chest tightness, They go hand in hand.’ (P5)
‘I didn’t choose chest tightness as a most important factor, because I had already chosen
doing activities at home.’ (P3)
Walking up hills
and stairs
0 3 ‘I think, we see a lot of severe COPD. So for a lot of them, not being able to walk up hills
and stairs is normal. For me it wouldn’t necessarily be an indicator of risk for
hospitalization.’ (P1)
‘I am always asking about exercise endurance and that are those questions around
breathlessness and exercise endurance.’ (P5)
Doing activities
at home
3 2 ‘I had doing activities at home as one of my top three. In terms of getting a better idea
how unwell that person is and whether they are struggling at home. In terms of how
long they have been unwell for. And yeah just giving me a better gage of just how
unwell they are.’ (P3)
‘In my experience you can have someone whose exercise endurance is declining, but that
doesn’t necessarily mean they are going to end up in hospital.’ (P1)
Confidence
leaving home
0 5 ‘I think a lot of our patients aren’t confident going out, because they are too debilitated
due to their lung condition.’ (P1)
‘I am just thinking, some days when you go and see somebody and you gather all your
information. Would I really be asking about confidence leaving home and their energy
levels? These questions may not equip in my assessment as much strongly as cough,
phlegm and can they speak in sentences and all that sort of stuff.’ (P3)
‘They can be less confident leaving home because they are more breathless than normal.







‘I have a lot of people that say: “I am really anxious, that is why I don’t sleep well.” So if
you just ask them “do you sleep soundly” and not backing them up in the context of
your respiratory symptoms, “do you sleep soundly and do you wake up during the
night with cough”, then that can sort of skew your results a little bit.’ (P5)
‘And as they get older they don’t have much sleep anyway. They have naps during the
day. So in night time it is limited. It is not always related to breathing.’ (P4)
‘It is just about what is waking you up from sleep. Is it going to the toilet? Is it the dog? Or
is it their breathing?’ (P1)
P1–P5: participant number.
aThe number of participants who ranked the CAT item as one of the three most important and the number of participants who ranked
the CAT item as one of the three least important CAT items on the risk of respiratory-related hospitalizations after the discussion.
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Table 3. Quotes of the focus group with respiratory physicians/advanced trainees and their ‘importance’ rankings of the
different CAT items in relation to respiratory-related hospitalizations.
Importance (number of
participant rankings)a
Items Most Least Quotes of participants
Cough 1 1 ‘I put cough as an important item, because for the patient to bring phlegm, they
need to cough.’ (P8)
‘Only if it is productive cough, they can also have dry cough.’ (P10)
‘If the cough score goes up, I think there is obviously an indication that the cough
goes up, which could indicate an airway inflammation. This means that they are
probably going to have an exacerbation.’ (P7)
‘I view it as, most patients with COPD have a chronic smokers cough and they are
just stable, I feel they may not necessarily come in. Unless they have chest
tightness or they are short of breath.’ (P11)







‘I would say the risk of exacerbation is depending on respiratory specific symptoms
which can be predictors of risk of exacerbation.’ (P7)
‘Activities, coughing a lot and probably feeling uncomfortable some of discomfort
will push them to the centre. Or chest tightness.’ (P8)
Walking up hills
and stairs
2 1 ‘Obviously walking up hills and stairs may be significant, but if they are at that stage
where they have difficulties doing day activities, showering, dressing, that really
reflects very severe on the risk of respiratory hospitalization.’ (P10)
‘Exercise actually is related to improvement. That is why rehabilitation is important.
Exercise in COPD patients is the most important part of rehabilitation.’ (P8)




6 0 ‘Patients are learning to live with their symptoms and their disability. But if they can’t
do their activities of daily living, that is pushing them somewhere else. To
supportive living which is hospitalisation.’ (P8)
‘I guess if you are asking sort of one key question, that would be about their
function.’ (P10)
‘And functional performance is important, and patients’ confidence and they are
predictors of hospital admissions, but as we said they are not linked necessarily to
COPD. They are influenced by comorbidities.’ (P8)
‘I would certainly rate their activities in the house as a pretty good marker of what
the average person should be able to do reasonably. So I would use that probably
as a leader.’(P6)




1 4 ‘So, confidence leaving home, it can be quite important as it is related to COPD. But
there are so many other things that can cause problems with that as well that it is
not really specific.’ (P10)
‘I am always interested in things provided by some sort of functional activity and the
context of the patient. That they are ending up housebound because no
confidence and no help at all.’ (P6)








‘Sleeping soundly, in elderly people sleep is disrupted for many reasons, and they
get used to that they have to go to the toilet in the middle of the night and
feeling sleepy and tired during the days. So I don’t think that predicts
hospitalisation.’ (P8)
‘I guess the problem is that there are somany other things that can affect energy.’ (P10)
‘It depends on how you phrase them. Does your respiratory condition prevent you from
sleeping soundly, then you can say that is very important. But there is still a 20% of
population who have a sleep disorder.’ (P10)
P6–P11: participant number.
aThe number of participants who ranked the CAT item as one of the three most important and the number of participants who ranked
the CAT item as one of the three least important CAT items on the risk of respiratory-related hospitalizations after the discussion.
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the clinical relevance of the adjusted CAT score alone
as a predictor of the risk of respiratory-related hospi-
talizations needs to be considered carefully. The
adjusted CAT score might be more helpful in asses-
sing the hospitalization risk in COPD patients when
combined with other factors that assess hospitaliza-
tion risk. Combining the adjusted CAT score, for
example, with the simple measure of ‘number of hos-
pitalizations in the year before assessment’,28,29 may
help the health care professional to generate quickly a
reliable indication of the patients’ risk of hospitaliza-
tions and thereby to make better management deci-
sions. This approach is in line with the GOLD 2016
Strategy5 encouraging multidimensional patient
assessment that addresses an individual’s symptoms
and/or health status, their severity of airflow limita-
tion and exacerbation history to stratify their risk of
adverse outcomes. However, large prospective valida-
tion is necessary to evaluate whether the adjusted
CAT adds any value beyond using the strong predic-
tor ‘prior hospitalizations’ alone when assessing hos-
pitalization risk. Likewise, it would be of further
interest to evaluate the validity of the adjusted CAT
for measuring health status (as well as the original
CAT9) in a wider range of COPD severities, to give
a better indication of the usefulness of the adjusted
CAT alone for the assessment of COPD patients.
Interestingly, the ARS score was related to
respiratory-related hospitalizations in our COPD pop-
ulation, in line with a paper describing an association
between the ARS score and all-cause hospital read-
mission in vulnerable patients of >65 years age.30 Use
of agents with anticholinergic effects is common in
patients with greater multimorbidity,31 and sensitivity
to these effects is expected to be greater in older peo-
ple.32 Both are common features in patients with
COPD.33 Moreover, inhaled anticholinergic drugs are
frequently prescribed for these patients. Further
Table 4. Derived algorithms of CAT scoring and the pre-
















Cough 1.0 2.0 1.0
Phlegm 1.0 2.0 1.5
Chest tightness 1.0 1.5 1.5
Breathlessness
while walking up
hills and stairs 1.0 1.0 1.0
Doing activities at
home 1.0 1.5 2.0
Confidence leaving
home 1.0 0.5 0.75
Sleep 1.0 0.5 0.5
Energy 1.0 0.5 0.5
Range of scores 0–40 0–47.5 0–43.75
Mean (SD) of




hospitalizations 0.094 0.047 0.099
CAT: COPD assessment test; SD: standard deviation.
ap-value of univariate associations between (adjusted) CAT scores
and future hospitalization frequency (infrequent (1/year) versus
frequent (>1/year)).
Table 5. Logistic multivariate regression model for




Adjusted CAT score (algorithm 1) 1.07 1.00–1.14 0.050
Frequent hospitalizations before
CAT (>1/year) 3.98 1.30–12.16 0.016
Presence of ischemic heart
disease and/or heart failure 0.17 0.05–0.62 0.007
Anticholinergic risk score scale
(score of 3) 3.08 0.87–10.89 0.081
CAT: COPD assessment test; OR: odds ratio; 95% CI: 95% con-
fidence interval.
aModel based on 76 patients with valid measurements. Explained
variance: 36.4%; 2 log-likelihood: 75.534.
Table 6. Logistic multivariate regression model for
respiratory-related hospitalizations (1/year vs. >1/year).a
Variable OR 95% CI p-Value
Original CAT score 1.07 0.99–1.17 0.072
Frequent hospitalizations
before CAT (>1/year) 4.20 1.38–12.80 0.012
Presence of ischemic heart
disease and/or heart failure 0.17 0.05–0.61 0.007
Anticholinergic risk score scale
(score of 3) 2.83 0.80–10.01 0.106
CAT: COPD assessment test; OR: odds ratio; 95% CI: 95% con-
fidence interval.
aModel based on 76 patients with valid measurements. Explained
variance: 35.5%; 2 log-likelihood: 76.168.
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prospective studies are warranted to explore the rela-
tion between the anticholinergic risk score and risk of
adverse outcomes in patients with COPD.
More evidence is also needed to explore the rela-
tionship between the presence of ischemic heart dis-
ease and/or heart failure and hospitalization risk in
patients with COPD. The strong but unexpected neg-
ative correlation we found between these factors was
in contrast with findings of previous studies.17 How-
ever, in a COPD self-management study, it was found
that patients who had comorbid cardiac disease were
more likely to adhere to their action plan for treatment
of their exacerbations.34 They may be ready to initiate
their treatment earlier and thereby avoid more severe
COPD exacerbations for which hospitalization would
be required. We cannot determine whether this was
the case in our study population, but the strength of
our finding also warrants further investigation.
In both of our focus groups and in literature, it was
suggested that some CAT items are influenced by
co-morbidities of patients with COPD,35 leading to
a higher total CAT score. Literature also shows that
co-morbidities often lead to an increase of hospitali-
zations in patients with COPD.17,36 More research
about the influence of co-morbid conditions on the
different CAT items and on respiratory-related hospi-
talizations is necessary and could be helpful to
develop the best CAT algorithm for predicting
respiratory-related hospitalizations.
The fact that the ‘Respiratory Integrated Care Ser-
vice’ patients have accounted for a relatively high
number of cases with frequent hospitalizations is not
surprising because having a high hospitalization risk
is a criterion for inclusion in this programme. Apart
from the hospitalization frequency, we do however
not have a clear explanation for the difference in CAT
scores between the databases. Overall, our study
results cannot be generalized to the whole COPD
patient population, as most patients had GOLD stage
III–IV and all received secondary healthcare. GOLD
stage could not be included in the multivariate
analyses because of the high number of missing spiro-
metry values; it was however related to respiratory-
related hospitalizations in the univariate analyses.
This is in line with previously published studies
data.28,29,37–39 Other variables not included in the
analyses because of insufficient data are exercise
capacity, physical activity and arterial oxygen satura-
tion (PaO2), even though they were associated with
respiratory-related events in previous studies.23,25,40–44
Using a prospective design in the future will allow
collecting a more complete set of variables for analy-
ses. In such a future study, it would be interesting to
include the patient’s perspective (by e.g. including a
patient focus group), because the CAT is developed as
a patient-reported outcome.9 Further, the generaliz-
ability of the results would increase by adding focus
groups incorporating healthcare providers with differ-
ent clinical experiences and from a variety of centres
and countries. Finally, we acknowledge that it would
have strengthened our conclusions if we had included a
longer follow-up and a larger patient population.
Conclusion
The adjusted CAT score described in this article may
help predict respiratory-related hospitalization risk in
severe and very severe patients with COPD who
receive secondary healthcare, especially in conjunc-
tion with prior hospitalizations. Further prospective
studies are necessary to confirm this.
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